Headquartered in London and publicly traded on the London Stock Exchange
AIM: POLB
Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world’s largest markets.
With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs.
Reasons to Invest
Experienced team with proven track record of closing significant transactions and exits
- Highly experienced management team with expertise in trial execution, deal-making, company building, and generating shareholder returns
- Cathal Friel, Co-Founder & Executive Chair – notable successes include co-founding Amryt Pharma plc which was acquired for US$1.48B in 2023, and hVIVO plc
- CEO Jeremy Skillington, PhD, was instrumental in Inflazome’s US$450M+ sale to Roche in 2020
High value clinical-stage programmes targeting critical unmet medical needs in large & growing markets
- POLB 001: Potentially breakthrough oral preventative therapy for cancer immunotherapy-induced CRS with FDA Orphan Drug Designation. POLB 001 has the potential to transform the cancer immunotherapy field, with a market opportunity of <US$10B1. By making cancer immunotherapy treatment safer through the prevention of the life-threatening side effect, CRS, POLB 001 has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals. As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.
- Oral encapsulated GLP-1 programme: A patient-friendly therapy targeting the growing obesity market using proprietary drug delivery technology. Oral GLP-1 options remain limited yet highly sought after, an effective oral GLP-1 could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments.
- Two successful AI-led discovery programmes: Transforming human challenge trial data into potential clinical candidates for RSV and influenza.
Financial runway into 2027, supporting near-term clinical value inflection points
- Debt free with cash runway into 2027
- Oversubscribed and upsized fundraise in June 2025, due to strong investor interest and demand
- POLB 001 TOPICAL trial patient recruitment and dosing expected to commence shortly. interim data expected summer 2026
- Oral GLP-1 proof of concept trial expected to commence H2 2026
Strong potential to secure partnerships based on positive data from clinical trials
- Cost-effective trials designed to produce high-quality proof of concept human data to accelerate partnering discussions with pharma to maximise value from programmes and generate shareholder returns
- Cancer immunotherapies & GLP-1 receptor agonists are large and fast-growing markets
- Strong IP, potential for protection out to at least 2044 for POLB 001
- Global, exclusive licensed rights for clinical stage assets
- FDA Orphan Drug Designation further validates POLB 001’s scientific rationale and strengthens its commercial appeal for prospective partners
- Team experienced in deal-making
POOLBEG PHARMA PLC – FY25 Results
29 April 2026
Get in touch with our investor relations team at